Chikungunya

Chikungunya vaccine seems convincing in phase 1 trial

  A recent study has shown encouraging results with most receivers developing neutralizing antibodies after one dose, according to a report published in The Lancet Infectious Diseases.The vaccine is based on an attenuated measles vaccine